Company / Financials
Whitehawk Therapeutics, Inc. Financials
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$26.0M
FY2025 · +6.7% YoY
Net Income
-$63.7M
FY2025 · +3.2% YoY
Profit Margin
-245.1%
FY2025 · net income / revenue
ROE
-121.4%
FY2025 · return on equity
Total Assets
$150.8M
FY2025
Total Debt
-
FY2025
Equity
$52.5M
FY2025
ROA
-42.2%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$26.0M+6.7% YoYNet Income HistoryProfit after all expenses and taxes-$63.7M+3.2% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$3.0M+7.7% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$67.5M+6.2% YoYSG&A Expense HistorySelling, general, and administrative expenses$36.7M-17.5% YoYR&D Expense HistoryResearch and development spending$51.0M+4.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$230.0KIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$2.36+3.3% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.36+3.3% YoY